The Neutrophil-to-lymphocyte Ratio (NLR) Predicts Short-term and Long-term Outcomes in Gastric Cancer Patients
Overview
Oncology
Affiliations
Background: The preoperative neutrophil-to-lymphocyte ratio (NLR) is a well-known prognostic marker for gastric cancer patients. However, the utility of the NLR in predicting short-term outcomes in gastric cancer patients remains unclear. Here, we investigated whether the preoperative NLR is a predictor of short-term outcomes in gastric cancer patients.
Methods: We retrospectively evaluated 154 consecutive gastric cancer patients. We compared the perioperative outcomes and median survival times (MSTs). In particular, for stage II/III (UICC, 7th edition) gastric cancer patients, we compared median disease-free survival time (MDFST) between the low- and high-NLR groups.
Results: Between the low-NLR group (n = 110) and the high-NLR group (n = 44), significant differences were observed in perioperative outcomes, including postoperative complications (3 (2.7%) vs. 5 (11.3%); p = 0.015), intraoperative blood loss (158 ± 168 g vs. 232 ± 433 g; p = 0.022), and intraoperative blood transfusions (0 vs. 3 (6.8%); p = 0.042). MSTs and MDFSTs were also significantly different (812 vs. 594 days, p = 0.04; and 848 vs. 475 days, p = 0.03, respectively). Multivariate analysis identified the NLR (hazard ratio [HR], 2.015; p = 0.004), Glasgow Prognostic Score (GPS) (HR, 1.533; p = 0.012), and presence of stage III/IV disease (HR, 5.488; p < 0.001), preoperative symptoms (HR, 3.412; p = 0.008), or postoperative complications (HR, 2.698; p < 0.001) as independent prognostic factors.
Conclusions: We suggest that the preoperative NLR is an additional useful predictor of both long-term and short-term outcomes in gastric cancer patients.
Ma X, Jiang X, Guo H, Wang J, Wang T, Lu X Langenbecks Arch Surg. 2025; 410(1):98.
PMID: 40080109 PMC: 11906490. DOI: 10.1007/s00423-025-03660-5.
Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.
Soltani-Tehrani A, Kumar A, Pohar K Transl Cancer Res. 2024; 13(11):6489-6502.
PMID: 39697728 PMC: 11651738. DOI: 10.21037/tcr-24-180.
Jing Y, Ren M, Li X, Sun X, Xiao Y, Xue J J Inflamm Res. 2024; 17:10273-10287.
PMID: 39654858 PMC: 11625636. DOI: 10.2147/JIR.S499094.
Fujita K, Omori T, Hara H, Shinno N, Yasui M, Wada H Surg Endosc. 2024; 39(1):269-279.
PMID: 39528658 DOI: 10.1007/s00464-024-11213-y.
Yang Y, Wang Z, Xin D, Guan L, Yue B, Zhang Q Front Immunol. 2024; 15:1468342.
PMID: 39512347 PMC: 11540680. DOI: 10.3389/fimmu.2024.1468342.